Chemeleon

Chemeleon's mission is to create simple, accessible, and affordable diagnostic solutions using its proprietary chemical sensor platform. The company's technology enables the detection of a broad range of analytes—including drugs, proteins, and viruses—in a sample-to-answer format visible to the naked eye, requiring no instruments or specialized training. A key strategic achievement is its clinical collaboration with Mayo Clinic to advance its instrument-free cardiac troponin assay for AMI detection. Chemeleon is positioned to transform point-of-care and point-of-need testing by empowering clinicians and consumers with rapid, decentralized diagnostics.

A proprietary chemical sensor platform that enables rapid, instrument-free, colorimetric detection of a broad range of analytes (drugs, proteins, viruses) in a sample-to-answer format visible to the naked eye.

Total raised: $16.1M

Chemeleon competes with established point-of-care diagnostic companies like Abbott, Roche, and Siemens that offer instrument-dependent troponin tests. Its main differentiation is the complete elimination of any reader or instrument, aiming to provide lab-accurate results with the simplicity of a lateral flow test, which could disrupt current care pathways if successfully validated.